Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: Implications for patient outcome

Clinical and Translational Oncology

Volumn 13, Issue 11, 2011, Pages 826-830

  Cubukcu, Erdem ^a   Olmez, Omer Fatih ^a   Saraydaroglu, Ozlem ^a   Akcali, Unsal ^a   Kanat, Ozkan ^a   Kurt, Ender ^a   Evrensel, Turkkan ^a   Manavoglu, Osman ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Excision repair cross complementing 1; Immunohistochemistry; Non small cell lung cancer; Prognosis

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MALE; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84856052532     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0741-7     Document Type: Article

References (17)

1. Ettinger DS, Akerley W, Bepler G et al (2010) Non-small cell lung cancer. J Natl Compr Canc Netw 8:740-801
2. Janku F, Stewart DJ, Kurzrock R (2010) Targeted therapy in non-small-cell lung cancer: Is it becoming a reality? Nat Rev Clin Oncol 7:401-414
3. Singh N, Bal A, Aggarwal AN et al (2010) Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers. Future Oncol 6:741-767
4. Socinski MA (2010) The emerging role of biomarkers in advanced non-small-cell lung cancer. Clin Lung Cancer 11:149-159
5. Gossage L, Madhusudan S (2007) Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33:565-577 (Pubitemid 47355341)
6. Simon GR, Ismail-Khan R, Bepler G (2007) Nuclear excision repair-based personalized therapy for non-small cell lung cancer: From hypothesis to reality. Int J Biochem Cell Biol 39:1318-1328 (Pubitemid 47031049)
7. Altaha R, Liang X, Yu JJ, Reed E (2004) Excision repair cross complementing-group 1: Gene expression and platinum resistance. Int J Mol Med 14:959-970
8. Vogel U, Dybdahl M, Frentz G, Nexo BA (2000) DNA repair capacity: Inconsistency between effect of over-expression of fi ve NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res 461:197-210
9. Vilmar A, Sørensen JB (2009) Excision repair cross-complementation group 1 (ERCC1) in platinum- based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature. Lung Cancer 64:131-139
10. Olaussen KA, Mountzios G, Soria JC (2007) ERCC1 as a risk stratifi er in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med 13:284-289 (Pubitemid 46847293)
11. Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991 (Pubitemid 44343542)
12. Kirschner K, Melton DW (2010) Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 30:3223-3232
13. Ren S, Zhou S, Zhang L et al (2010) High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Invest 28:1078-1083
14. Andressoo JO, Hoeijmakers JH, de Waard H (2006) Nucleotide excision repair and its connection with cancer and ageing. Adv Exp Med Biol 570:45-83
15. Hwang IG, Ahn MJ, Park BB et al (2008) ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 113:1379-1386
16. Fujii T, Toyooka S, Ichimura K et al (2008) ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 59:377-384 (Pubitemid 351335101)
17. Matos LL, Trufelli DC, de Matos MG, da Silva Pinhal MA (2010) Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomark Insights 5:9-20